Zacks Investment Research on MSN4d
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou ...
Pharmabiz2d
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...
The Pharma Letter4d
Bayer secures global rights to PRMT5 inhibitor
German drugmaker Bayer (BAYN: DE) has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive ...
BioSpace5d
Bayer Jumps on Chinese Partnership Train with Oncology Deal
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced that they have entered into a global license agreement for Puhe BioPharma's oral, small ...
PharmiWeb4d
Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...